A team led by KOH Gou Young, director of the Center for Vascular Research, within the Institute for Basic Science (IBS), in collaboration with Chungnam National University, clarified the molecular mechanism to explain how the thyroid and surrounding vascular system change in the most common form of hyperthyroidism. Published in the EMBO Molecular Medicine journal, these findings provide a potential therapeutic target for thyroid diseases.

"Previous studies show that abnormalities in thyroid glands and surrounding vasculature are interconnected, we wanted to understand how this happens, at the molecular level," explains Koh.

Using animal models that simulate Graves' disease, IBS scientists uncovered the biological pathway contributing to this disorder. They found that the culprit is the vascular endothelial growth factor A (VEGF–A). This protein is involved in forming new vessels around the thyroid, and regulating the hormonal exchange happening between these vessels and the thyroid, through very small pores called fenestrae.

Upon stimulation with the thyrotropin hormone, VEGF–A is produced by the thyroid gland and as a result, the thyroid enlarges and the walls of the capillaries increase the expression of VEGFR2, the receptor for VEGF–A.

By blocking VEGFR2, IBS scientists could inhibit enlargement of the thyroid and stop vascular remodeling. "Our findings identify VEGFR2 blockade as a novel therapeutic avenue for targeting thyroid disease associated with thyrotropin," explains Koh.

Concurrently, the research team could also exclude other molecular pathways. For example, they found that the angiopoietin–Tie2 pathway, fundamental in other tissues like the eyes and brain, does not play a major role in remodeling the vasculature of the thyroid gland. Finally, VEGFR3 was ruled out from the indispensable pool of proteins that maintain thyroid vascular integrity.